BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

AURINIA PHARMACEUTICALS — Lobbying — Receipts Report

LD-2 disclosure · 1st Quarter - Termination

AURINIA PHARMACEUTICALS

via THE ROSS GROUP, LLC

1st Quarter (Jan 1 - Mar 31) · 2019Posted Apr 30, 2019Filing document ↗LDA record ↗

Income$23Kfee reported

Client

Name: AURINIA PHARMACEUTICALS
Description: biotech development and commercialization
Location: Canada

Registrant

Firm: THE ROSS GROUP, LLC
Description: policy and consulting
Location: Arlington, Virginia, United States of America

Lobbying activities

1 issue

Health Issues
drug pricing and coverage lupus nephritis
LobbyistsSHALLA ROSS
Covered position (SHALLA ROSS): see prior filing
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.